# Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

> **NCT03566316** · PHASE3 · COMPLETED · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 134 (actual)

## Conditions studied

- Hypertension With Hyperlipidemia

## Interventions

- **DRUG:** Telmisartan/Amlodipine
- **DRUG:** Rosuvastatin
- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT03566316
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-24
- **Primary completion:** 2017-06-16
- **Final completion:** 2017-06-16
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566316, "Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03566316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*